111 related articles for article (PubMed ID: 33099934)
21. Long-term survival in patients with recurrent glioblastoma treated with bevacizumab: a multicentric retrospective study.
Morisse MC; Etienne-Selloum N; Bello-Roufai D; Blonski M; Taillandier L; Lorgis V; Noël G; Ahle G; Durán-Peña A; Boone M; Chauffert B
J Neurooncol; 2019 Sep; 144(2):419-426. PubMed ID: 31325146
[TBL] [Abstract][Full Text] [Related]
22. Randomized Phase II Evaluation of Bevacizumab Versus Bevacizumab Plus Fosbretabulin in Recurrent Ovarian, Tubal, or Peritoneal Carcinoma: An NRG Oncology/Gynecologic Oncology Group Study.
Monk BJ; Sill MW; Walker JL; Darus CJ; Sutton G; Tewari KS; Martin LP; Schilder JM; Coleman RL; Balkissoon J; Aghajanian C
J Clin Oncol; 2016 Jul; 34(19):2279-86. PubMed ID: 27217446
[TBL] [Abstract][Full Text] [Related]
23. Bevacizumab toxicity in heavily pretreated recurrent epithelial ovarian, fallopian tube, and primary peritoneal cancers.
Martin JY; Urban RR; Liao JB; Goff BA
J Gynecol Oncol; 2016 Sep; 27(5):e47. PubMed ID: 27329195
[TBL] [Abstract][Full Text] [Related]
24. Efficacy and toxicity of bevacizumab in recurrent ovarian disease: an update meta-analysis on phase III trials.
Marchetti C; De Felice F; Palaia I; Musella A; Di Donato V; Gasparri ML; Musio D; Muzii L; Tombolini V; Panici PB
Oncotarget; 2016 Mar; 7(11):13221-7. PubMed ID: 26657509
[TBL] [Abstract][Full Text] [Related]
25. Randomized phase II trial of bevacizumab plus everolimus versus bevacizumab alone for recurrent or persistent ovarian, fallopian tube or peritoneal carcinoma: An NRG oncology/gynecologic oncology group study.
Tew WP; Sill MW; Walker JL; Secord AA; Bonebrake AJ; Schilder JM; Stuckey A; Rice L; Tewari KS; Aghajanian CA
Gynecol Oncol; 2018 Nov; 151(2):257-263. PubMed ID: 30177462
[TBL] [Abstract][Full Text] [Related]
26. Should bevacizumab be continued after progression on bevacizumab in recurrent ovarian cancer?
Backes FJ; Richardson DL; McCann GA; Smith B; Salani R; Eisenhauer EL; Fowler JM; Copeland LJ; Cohn DE; O'Malley DM
Int J Gynecol Cancer; 2013 Jun; 23(5):833-8. PubMed ID: 23640292
[TBL] [Abstract][Full Text] [Related]
27. Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer.
Cannistra SA; Matulonis UA; Penson RT; Hambleton J; Dupont J; Mackey H; Douglas J; Burger RA; Armstrong D; Wenham R; McGuire W
J Clin Oncol; 2007 Nov; 25(33):5180-6. PubMed ID: 18024865
[TBL] [Abstract][Full Text] [Related]
28. Addition of bevacizumab to weekly paclitaxel significantly improves progression-free survival in heavily pretreated recurrent epithelial ovarian cancer.
O'Malley DM; Richardson DL; Rheaume PS; Salani R; Eisenhauer EL; McCann GA; Fowler JM; Copeland LJ; Cohn DE; Backes FJ
Gynecol Oncol; 2011 May; 121(2):269-72. PubMed ID: 21315428
[TBL] [Abstract][Full Text] [Related]
29. Addition of bevacizumab to chemotherapy in patients with ovarian cancer: a systematic review and meta-analysis of randomized trials.
Li J; Zhou L; Chen X; Ba Y
Clin Transl Oncol; 2015 Sep; 17(9):673-83. PubMed ID: 25990506
[TBL] [Abstract][Full Text] [Related]
30. Efficacy and safety results from OCTAVIA, a single-arm phase II study evaluating front-line bevacizumab, carboplatin and weekly paclitaxel for ovarian cancer.
Gonzalez-Martin A; Gladieff L; Tholander B; Stroyakovsky D; Gore M; Scambia G; Kovalenko N; Oaknin A; Ronco JP; Freudensprung U; Pignata S;
Eur J Cancer; 2013 Dec; 49(18):3831-8. PubMed ID: 24007819
[TBL] [Abstract][Full Text] [Related]
31. Neoadjuvant Chemotherapy Followed by Maintenance Therapy With or Without Bevacizumab in Unresectable High-Grade Serous Ovarian Cancer: A Case-Control Study.
Petrillo M; Paris I; Vizzielli G; Amadio G; Cosentino F; Salutari V; Scambia G; Fagotti A
Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S952-8. PubMed ID: 26036187
[TBL] [Abstract][Full Text] [Related]
32. Activity of Bevacizumab in Patients With Low-Grade Serous Ovarian Carcinoma.
Rose PG; Mahdi H; Jernigan A; Yang B
Int J Gynecol Cancer; 2016 Jul; 26(6):1048-52. PubMed ID: 27258727
[TBL] [Abstract][Full Text] [Related]
33. Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial.
Oza AM; Cook AD; Pfisterer J; Embleton A; Ledermann JA; Pujade-Lauraine E; Kristensen G; Carey MS; Beale P; Cervantes A; Park-Simon TW; Rustin G; Joly F; Mirza MR; Plante M; Quinn M; Poveda A; Jayson GC; Stark D; Swart AM; Farrelly L; Kaplan R; Parmar MK; Perren TJ;
Lancet Oncol; 2015 Aug; 16(8):928-36. PubMed ID: 26115797
[TBL] [Abstract][Full Text] [Related]
34. A phase 3 randomized, open-label, multicenter trial for safety and efficacy of combined trabectedin and pegylated liposomal doxorubicin therapy for recurrent ovarian cancer.
Monk BJ; Herzog TJ; Wang G; Triantos S; Maul S; Knoblauch R; McGowan T; Shalaby WSW; Coleman RL
Gynecol Oncol; 2020 Mar; 156(3):535-544. PubMed ID: 31924332
[TBL] [Abstract][Full Text] [Related]
35. Long-term outcomes of patients with recurrent ovarian cancer treated with a polyvalent vaccine with bevacizumab combination.
Kahn RM; Ragupathi G; Zhou QC; Iasonos A; Kravetz S; Hensley ML; Konner JA; Makker V; Tew WP; Aghajanian C; Sabbatini PJ; O'Cearbhaill RE
Cancer Immunol Immunother; 2023 Jan; 72(1):183-191. PubMed ID: 35779095
[TBL] [Abstract][Full Text] [Related]
36. Platinum-resistant recurrent ovarian cancer with long survival on bevacizumab and gemcitabine.
Komiyama S; Kugimiya T; Takeya C; Takahashi R; Kubushiro K
J Obstet Gynaecol Res; 2018 Jul; 44(7):1330-1334. PubMed ID: 29767464
[TBL] [Abstract][Full Text] [Related]
37. Impact of bevacizumab containing first line chemotherapy on recurrent disease in epithelial ovarian cancer: A case-control study.
Petrillo M; Amadio G; Salutari V; Paris I; Di Stefano MG; Ferandina G; Scambia G; Fagotti A
Gynecol Oncol; 2016 Aug; 142(2):231-6. PubMed ID: 27215633
[TBL] [Abstract][Full Text] [Related]
38. An international, phase III randomized trial in patients with mucinous epithelial ovarian cancer (mEOC/GOG 0241) with long-term follow-up: and experience of conducting a clinical trial in a rare gynecological tumor.
Gore M; Hackshaw A; Brady WE; Penson RT; Zaino R; McCluggage WG; Ganesan R; Wilkinson N; Perren T; Montes A; Summers J; Lord R; Dark G; Rustin G; Mackean M; Reed N; Kehoe S; Frumovitz M; Christensen H; Feeney A; Ledermann J; Gershenson DM
Gynecol Oncol; 2019 Jun; 153(3):541-548. PubMed ID: 31005287
[TBL] [Abstract][Full Text] [Related]
39. The Role of a Single Angiogenesis Inhibitor in the Treatment of Recurrent Glioblastoma Multiforme: A Meta-Analysis and Systematic Review.
Wang Y; Xing D; Zhao M; Wang J; Yang Y
PLoS One; 2016; 11(3):e0152170. PubMed ID: 27007828
[TBL] [Abstract][Full Text] [Related]
40. Minimal residual disease at primary debulking surgery versus complete tumor resection at interval debulking surgery in advanced epithelial ovarian cancer: A survival analysis.
Ghirardi V; Moruzzi MC; Bizzarri N; Vargiu V; D'Indinosante M; Garganese G; Pasciuto T; Loverro M; Scambia G; Fagotti A
Gynecol Oncol; 2020 Apr; 157(1):209-213. PubMed ID: 31952843
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
